Nascent Biologics co-founder Mark C. Glassy has co-authored a new paper entitled “Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.” Published in Human Antibodies 18, the paper covers the performance of pritumumab in patients with brain cancer. The bottom line: Pritumumab appears to be a safe and effective […]
This author has yet to write their bio.Meanwhile lets just say that we are proud Nascent contributed a whooping 32 entries.
Entries by Nascent
SAN DIEGO – Mark Glassy, PhD, Chief Executive Officer and Co-founder of Nascent Biologics, Inc., (NBI), scientific researcher and inventor, announced today that he has recovered the license on his invention, “Pritumumab,” the first human antibody that has been used to treat cancer patients, after a 27 year absence in Japan. Dr. Glassy invented Pritumumab, […]